| Title |
Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze
|
|---|---|
| Published in |
Psychopharmacology, April 1995
|
| DOI | 10.1007/bf02245945 |
| Pubmed ID | |
| Authors |
T. H. Privette, D. M. Terrian |
| Abstract |
The selective kappa agonist U-50,488H was evaluated on the elevated plus-maze test of anxiety. U-50,488H was administered intraperitoneally to male Sprague-Dawley rats 20 min before testing, first in an open field apparatus, then followed immediately on the elevated plus-maze. No significant change in spontaneous locomotor activity was measured in the open field apparatus, suggesting that U-50,488H was devoid of sedative effects in the dose range tested (0.1-1000 micrograms/kg, IP). Doses between 10 and 1000 micrograms/kg produced significant increases in elevated plus-maze behavior that were consistent with anxiolytic actions for U-50,488H. These anxiolytic-like effects were antagonized by naloxone (2.0 mg/kg, IP), suggesting an opioid receptor site of action. In addition, we tested the kappa 1-selective U-50,488H-derivative, U-69,593 (100 micrograms/kg, IP), which was also shown to mimic the anxiolytic-like effects produced by U-50,488H. These results suggest that low doses of the selective kappa 1 agonists U-50,488H and U-69,593 are endowed with anxiolytic properties in rodents and that the kappa opioid system may be involved in the behavioral response to anxiety. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 3% |
| Unknown | 28 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 21% |
| Student > Master | 5 | 17% |
| Researcher | 3 | 10% |
| Other | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Other | 5 | 17% |
| Unknown | 5 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 24% |
| Medicine and Dentistry | 5 | 17% |
| Neuroscience | 5 | 17% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 4 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2011.
All research outputs
#4,696,781
of 22,789,566 outputs
Outputs from Psychopharmacology
#1,230
of 5,346 outputs
Outputs of similar age
#3,206
of 25,099 outputs
Outputs of similar age from Psychopharmacology
#5
of 31 outputs
Altmetric has tracked 22,789,566 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,346 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 25,099 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.